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Direct Intrathecal Implantation of Mesenchymal Stromal Cells 
Leads to Enhanced Neuroprotection via an NFκB-Mediated 
Increase in Interleukin-6 Production
Peter A. Walker,1,2 Matthew T. Harting,1,2 Fernando Jimenez,2 Shinil K. Shah,1,2,4 Shibani Pati,1 
Pramod K. Dash,3 and Charles S. Cox, Jr1,2,4
Mesenchymal stromal cell (MSC) therapy has shown promise for the treatment of traumatic brain injury (TBI). 
Although the mechanism(s) by which MSCs offer protection is unclear, initial in vivo work has suggested that 
modulation of the locoregional infl ammatory response could explain the observed benefi t. We hypothesize that 
the direct implantation of MSCs into the injured brain activates resident neuronal stem cell (NSC) niches altering 
the intracerebral milieu. To test our hypothesis, we conducted initial in vivo studies, followed by a sequence of in 
vitro studies. In vivo: Sprague-Dawley rats received a controlled cortical impact (CCI) injury with implantation 
of 1 million MSCs 6 h after injury. Brain tissue supernatant was harvested for analysis of the proinfl ammatory 
cytokine profi le. In vitro: NSCs were transfected with a fi refl y luciferase reporter for NFκB and placed in contact 
culture and transwell culture. Additionally, multiplex, quantitative PCR, caspase 3, and EDU assays were com-
pleted to evaluate NSC cytokine production, apoptosis, and proliferation, respectively. In vivo: Brain supernatant 
analysis showed an increase in the proinfl ammatory cytokines IL-1α, IL-1β, and IL-6. In vitro: NSC NFκB activity 
increased only when in contact culture with MSCs. When in contact with MSCs, NSCs show an increase in IL-6 
production as well as a decrease in apoptosis. Direct implantation of MSCs enhances neuroprotection via acti-
vation of resident NSC NFκB activity (independent of PI3 kinase/AKT pathway) leading to an increase in IL-6 
production and decrease in apoptosis. In addition, the observed NFκB activity depends on direct cell contact.
Introduction
Approximately 1.5 million people suffer traumatic brain injury (TBI) yearly in the United States. The annual mor-
tality approaches 50,000 with the remaining patients suffer-
ing from varying levels of long-term sequelae [1]. Overall, 
6.5 million patients are burdened by the physical, cognitive, 
and psychosocial defi cits associated with TBI [2] leading to a 
total economic impact of ~60 billion dollars [3,4].
Bone marrow and umbilical cord blood-derived mes-
enchymal stromal cells (MSCs) have shown potential as a 
novel therapy for a number of central nervous system dis-
orders including TBI [5], ischemic stroke [6], and spinal 
cord injury [7]. Initial in vivo research has shown MSC 
engraftment at the site of injury with possible differentia-
tion into neuronal cells [8,9]; however, despite the promising 
results of initial studies, doubt remains about the frequency 
of transdifferentiation and the clinical signifi cance of cellu-
lar engraftment [4,10,11].
While the mechanism of action remains unknown, modu-
lation of infl ammatory cytokine production could represent 
a mechanism for neuroprotection. In vitro, human MSCs co-
cultured with subpopulations of immune cells showed an 
increase in production of the anti-infl ammatory cytokines 
interleukins (IL)-4 and IL-10 with a concomitant decrease 
in the proinfl ammatory cytokines tumor necrosis factor 
(TNF)-α and interferon (IFN)-γ [12]. Additionally, intra-
venous infusion of MSCs was associated with an increase 
in serum IL-10 in a murine sepsis model [13]; however, 
the effect of MSCs on the intracerebral microenvironment 
after neural injury remains controversial. Recently, MSCs 
directly implanted into the normal rat hippocampus were 
found to stimulate an infl ammatory response as evidenced 
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Next, 2 groups (n = 3) of NSCs and MSCs were placed 
in direct contact co-culture (1 group stimulated with TNFα 
for 6 h). Using an EdU proliferation assay kit (Invitrogen, 
Carlsbad, CA), the fraction of actively dividing NSCs was 
calculated using fl ow cytometry in order to investigate the 
effect of MSCs on NSC proliferation in vitro.
Additionally, separate NSC/MSC co-cultures (n = 3) were 
placed in glucose-free media and incubated in an oxygen-
free environment for 6 h to stress the cells. Using a caspase 
3 antibody (Cell Signaling Inc., Danvers, MA), the fraction of 
apoptotic NSCs was measured using fl ow cytometry.
Methods
All protocols involving the use of animals were in com-
pliance with the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals and were approved by 
the University of Texas Institutional Animal Care and Use 
Committee (protocol HSC-AWC-07-055).
Data Analysis
Unless otherwise indicated, all values are represented as 
mean ± SEM. Values were compared using analysis of vari-
ance (ANOVA) with a post-hoc Tukey analysis. A P value of 
≤0.05 was used to denote statistical signifi cance.
In vivo
Controlled cortical impact injury. A CCI device (eCCI Model 
6.3; VCU, Richmond, VA) was used to administer a unilateral 
brain injury as described previously [17]. The 225–250 g male 
rats were anesthetized with 4% isofl urane and a 1:1 mixture 
of N2O/O2 and the head was mounted in a stereotactic frame. 
With the head held in a horizontal plane, a midline incision 
and subsequent 7- to 8-mm craniectomy was performed on 
the right cranial vault. The center of the craniectomy was 
placed at the midpoint between bregma and lambda, 3 mm 
lateral to the midline, overlying the tempoparietal cortex. 
Animals received a single impact of 3.1-mm depth of defor-
mation with an impact velocity of 5.8 m/s and a dwell time 
of 150 ms (moderate-to-severe injury) at an angle of 10° 
from the vertical plane using a 6-mm diameter impactor 
tip, making the impact orthogonal to the surface of the cor-
tex. The impact was delivered onto the parietal association 
cortex. Sham injuries were performed by anesthetizing the 
animals, making the midline incision, and separating the 
skin, connective tissue, and aponeurosis from the cranium. 
The incision was then closed. The body temperature was 
maintained at 37°C by the use of a heating pad. Previously 
obtained serial arterial PaO2 and PaCO2 measurements have 
shown that animals do not become hypoxic or hypercarbic 
during this procedure [16].
Preparation and intracerebral placement of MSCs. After 
expansion per protocol, MSCs were collected and suspended 
in the phosphate-buffered saline (PBS) vehicle. Cells were 
checked for viability via Trypan blue exclusion and counted 
using a hemocytometer. MSCs were then suspended at a 
concentration of 10,000 c/μL. Immediately prior to intracere-
bral cell placement, the cells were titrated gently 8–10 times 
to ensure a homogeneous mixture of cells.
Six hours after CCI, rats were again anesthetized as de-
scribed earlier and the head was mounted in a stereotactic 
by infi ltration of ED1-positive microglia/macrophages and 
astrogliosis with failure of engraftment at 14 days [14].
After direct intracerebral implantation in a TBI model, 
MSCs are in contact with neurons, astrocytes, glial cells, and 
neural stem cells (NSCs). Endogenous NSC proliferation 
is thought to be critical to the neuroreparative response to 
injury. The focus of this study was to investigate the effect 
of MSC implantation on cytokine production in vivo and to 
evaluate the potential role of NF-kappa B (NFκB) activation 
in NSCs in vitro. Previous work has shown that late NFκB 
activation can provide endogenous neuroprotection and up-
regulation of antiapoptotic molecules in a hypoxia–ischemia 
model [15]. To test our hypothesis, a series of in vivo and 
in vitro experiments were performed to evaluate poten-
tial MSC modulation of infl ammatory cytokine production 
focusing on an NFκB-dependent pathway.
Experimental Design
In vivo
Three groups (n = 6) of Sprague-Dawley rats underwent 
controlled cortical impact (CCI) injury (2 groups) or sham 
injury (1 group). Previously isolated MSCs were stereotacti-
cally injected into the injury cavity and penumbra 6 h after 
injury as previously described [16]. Next, 6 h after MSC injec-
tion, the brain tissue was homogenized and the supernatant 
collected. Using a Bio-Plex cytokine assay system (Bio-Rad 
Laboratories, Hercules, CA), the intracerebral infl ammatory 
cytokine levels were measured.
The additional 2 groups (n = 6) of Sprague-Dawley rats 
underwent CCI. Six hours after injury 1 group received ste-
reotactic injection of 1 million QDOT-labeled MSCs with 
the second group serving as a control. The animals were 
perfused with paraformaldehyde and the brain tissue was 
fi xed. Subsequently, the tissue was sectioned and the brains 
were viewed using fl uorescent microscopy to observe MSC 
engraftment.
In vitro
To evaluate the change in cytokine production observed 
in vivo, NSCs were transfected with a fi refl y luciferase 
reporter for NFκB. The transfected cells were placed in 
direct contact co-culture with MSCs (1 group stimulated 
with TNFα) to investigate the effect of increasing MSC con-
centration on NFκB activation. Furthermore, NSCs were 
placed in transwell (non-contact) co-culture to evaluate the 
need for direct cell contact and transfected with dominant 
negative vectors for IKKβ, AKT (K179M), and the PI3 kinase 
inhibitor LY294002 to analyze the potential mechanism of 
NFκB activation. Of note, all NFκB transfection groups con-
tained 4 samples (n = 4).
In order to investigate infl ammatory cytokine production 
in vitro, 2 groups of NSCs and MSCs were placed in direct 
contact co-culture (1 group stimulated with TNFα; n = 6). 
After 6 h of incubation, cytokine levels were measured in 
the media using the Bio-Plex cytokine assay system (Bio-
Rad Laboratories, Hercules, CA). To further investigate the 
source of IL-6 production, a quantitative real-time PCR was 
completed on separate groups of direct contact co-cultures 
after fl ow cytometric sorting of MSCs based upon CD29 and 
Stro-1 positivity.
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previously described [18]. The manufacturer’s protocol was fol-
lowed to culture and expand the NSCs as neurospheres. Cells 
between passages 2 and 4 were utilized for all experiments.
Neural Stem Cell (NSC) transfection. NSCs were allowed 
to expand in culture using NSC growth media (Invitrogen, 
Carlsbad, CA). After 48 h in culture, the cells were sepa-
rated from the plates using 0.25% trypsin and placed into 
24-well plates at a density of 2.5 × 104 cells per well. After 
24 h of incubation, the cells were transfected with a fi refl y 
luciferase NFκB vector and Renilla luciferase standard 
using Lipofectamine 2000 per the manufacturer’s protocol 
(Invitrogen). In brief, 4 μg of an NFκB vector was placed in 50 
μL of OPTIMEM buffer solution and 2 μL of Lipofectamine 
was added to 48 μL of OPTIMEM. Both were allowed to in-
cubate at room temperature for 5 min. At this point, the 2 
solutions were combined and allowed to incubate for an ad-
ditional 20 min. One hundred microliters of the combined 
Lipofectamine/NFκB vector was added to each well. After 
4 h of incubation, the solution was replaced with warmed 
media. The samples were allowed to incubate for 24 h.
In addition to the NFκB vector, NSC samples were trans-
fected with and without dominant negative vectors for IKKβ, 
AKT (K179M), and the PI3 kinase inhibitor LY294002. This 
was completed by adding 0.25 μg of IKKβ and AKT (K179M) 
or 20 mM of LY294002 with the NFκB vector at the time of 
transfection.
Twenty-four hours after transfection, MSCs were placed 
in direct (contact) co-culture and transwell (no contact) cul-
ture with the NSC samples at varying densities to investigate 
a potential dose response. Next, the samples were stimu-
lated for 6 h with 10 ng/mL of TNFα. The samples were then 
washed with phosphate-buffered saline and subsequently 
placed at −80°C for lysis.
Measurement of luciferase activity. Measurement of the 
NFκB fi refl y and Renilla luciferase activity was completed 
with the Dual Luciferase Reporter Assay System (Promega, 
Madison, WI). In brief, 100 μL of passive lysis buffer solution 
was added to each sample well. The plates were placed on 
shaker for 15 min to allow complete cell lysis. For each sam-
ple, 10 μL of lysed cell solution was added to 100 μL of pri-
mary NFκB luciferase reporter and placed in luminometer 
(Berthold Inc., Oak Ridge, TN). Of note, the luminometer 
was set for 2 s lag time with 10 s read time. Once value was 
recorded, 100 μL of secondary Renilla luciferase reporter 
was added and sample was replaced in luminometer for 
measurement.
IL-6 immunohistochemistry. NSCs were allowed to expand 
in culture using NSC growth media (Invitrogen, Carlsbad, 
CA). After 48 h in culture, the cells were separated from the 
plates using 0.25% trypsin and placed into 24-well plates at a 
density of 2.5 × 104 cells per well. After 24 h incubation, 2.5 
× 104 MSCs were placed in direct co-culture with the NSC 
population. The co-culture was allowed to incubate over-
night followed by 6 h of stimulation with 10 ng/mL of TNFα. 
A conjugated CD29-PE antibody (BD Biosciences, San Jose, 
CA) was added to differentiate the different cell types (1 h 
incubation). Next, the co-cultures were fi xed with 4% para-
formaldehyde (30 min), permeabilized in 0.5% Triton X-100 
(30 min), blocked in 4% FBS–PBS (30 min), and incubated 
with IL-6 antibody (Abcam Inc., Cambridge, MA) overnight. 
Next, a FITC secondary antibody (Zymed Inc., San Francisco, 
CA) was added. Finally, the co-cultures were viewed with 
fl uorescent microscopy.
frame. The midline incision was opened and the injured 
brain was exposed. A 25-gauge microinjection needle was 
used to stereotactically guide the placement of the cells in 
the area of injury and the penumbral area. At all 12 injec-
tion sites, 8.3 μL PBS containing 83,000 MSCs was injected 
over 10 s at 2–3 mm below the cortex, for a total placement 
of 1 × 106 MSCs per treatment animal. Sham treatment ani-
mals underwent identical procedures, with the injections 
only consisting of the PBS vehicle [18]. The incisions were 
closed and the animals allowed to recover.
Brain homogenate supernatant fl uid collection. Three groups 
of 6 rats underwent a CCI injury (2 groups) or sham injury (1 
group). The groups were sacrifi ced at 6 h after CCI or sham 
injury. Their brains were extracted and 4 regions (consist-
ing of coronal sections of entire hemisphere), relative to the 
injury, were isolated: the site of direct injury, penumbral 
region, ipsilateral frontal region, and contralateral region 
as we have previously described [17]. The sections were 
weighed to ensure each section was 120 mg, gently minced 
with a pellet pestle, diluted in low-glucose DMEM (Gibco, 
Carlsbad, CA), vortexed for 30 s, and centrifuged for 6 min at 
1,000g. The supernatant, containing intracerebral, interstitial 
fl uid, was collected [16].
Cytokine analysis. Cytokines were detected in the brain 
homogenate supernatant fl uid and NSC/MSC co-culture 
supernatant using the Bio-Plex cytokine assay system (Bio-
Rad Laboratories, Hercules, CA). Concentrations of IL-1α, 
IL-1β, IL-2, IL-4, IL-6, IL-10, IFN-γ, granulocyte macrophage 
colony-stimulating factor, and TNFα were simultaneously 
evaluated using a commercially available multiplex bead-
based immunoassay (Rat 9-Plex; Bio-Rad Laboratories). 
The assay was performed per the manufacturer’s instruc-
tions and the details have been previously published by our 
group and others [19,20]. High standard curves (low RP1 tar-
get value) for each soluble cytokine were used, ranging from 
2 to 32,000 pg/mL. A minimum of 100 beads per cytokine 
region were evaluated and recorded. Values with a coeffi -
cient of variation beyond 10% were not included in fi nal data 
analysis. All samples were run in duplicate [21].
Immunohistochemistry. Brains from sacrifi ced rats were 
placed in paraformaldehyde for at least 24 h. After tissue 
processing, the tissues were embedded in formalin and cut 
into ~50 μm sections and placed on slides. After deparafi niz-
ing, the tissue sections were stained with 4′,6-diamidino-2-
phenylindole (DAPI) (for nuclear visualization) (Invitrogen, 
Carlsbad, CA) and visualized with fl uorescent microscopy.
In vitro
Isolation, characterization, and labeling of rat mesenchymal stem 
cells. MSCs were isolated from the bone marrow of Sprague-
Dawley rats and expanded in MAPC media as previously 
described [22]. Flow cytometric immunophenotyping was 
used to ensure that the MSCs were CD11b−, CD45−, CD29+, 
CD49e+, CD73+, CD90+, CD105+, and Stro-1+. MSCs were 
labeled with the Qtracker 655 cell-labeling kit (Invitrogen, 
Carlsbad, CA) per the manufacturer’s protocol. Cell-labeling 
effi ciency was greater than 90%. MSCs between passages 3 
and 5 were utilized for all experiments.
Isolation and characterization of rat neural stem cells. NSCs 
were purchased from Alphagenix (Alphagenix, Inc., Sioux 
Falls, SD). Flow cytometric immunophenotyping was used 
to ensure the NSCs were nestin+ and GFAP− as we have 
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for 6 h with 10 ng/mL of TNFα. At this point 15 mM of EdU 
was added and allowed to incubate for 1 h. Next, we washed 
the cells with 4% bovine serum in DMEM (4% FBS) and then 
added an antibody to CD29 to differentiate the NSCs and 
MSCs using the fl ow cytometer. After 30 min of incubation, 
the cells were washed and fi xed with paraformaldehyde. This 
step was repeated twice to permeabilize the cells and then 
the anti-EdU antibody “cocktail” provided by the manufac-
turer was added. Finally, the cells were washed followed by 
the addition of Ribonuclease and CellCycle488-Red stain to 
analyze the cell cycle distribution using fl ow cytometry.
Caspase 3 assay. NSCs were allowed to expand in culture 
using NSC growth media (Invitrogen, Carlsbad, CA). After 
48 h in culture, the cells were separated from the plates using 
0.25% trypsin and placed into 6-well plates at a density of 1.0 
× 105 cells per well. After 24 h incubation, 1.0 × 105 MSCs 
were placed in direct co-culture with the NSC population. 
The co-cultures were washed and glucose-free media was 
added to each well. Next, the co-cultures were placed in an 
oxygen-deprived environment for 6 h. The co-cultures were 
then fi xed with 4% paraformaldehyde (30 min), permeabi-
lized in 0.5% Triton X-100 (30 min), blocked in 4% FBS–PBS 
(30 min) and incubated with FITC-conjugated caspase 3 anti-
body (Cell Signaling Inc., Danvers, MA) and APC-conjugated 
nestin (BD Biosciences, San Jose, CA) for 1 h. Finally, using 
fl ow cytometry, the caspase positivity was measured.
Results
In vivo
Cytokine analysis of brain tissue lysate 6 h after direct 
implantation of MSCs in a rat TBI model showed an increase 
in the cytokines IL-1α (penumbral region), IL-1β (penum-
bral region), IL-6 (direct injury area and penumbral region), 
and TNFα (penumbral region) compared to vehicle control 
(Table 2).
Immunohistochemistry after MSC implantation showed 
3%–5% of the implanted MSCs to be located in the brain. Of 
the MSCs located in the brain, 73% were located on the side 
ipsilateral to the cortical injury, 58% were found in the ven-
tricles (Fig. 1A), and 26% were found in the direct injury and 
penumbral areas. Figure 1B shows MSCs located around a 
needle tract 6 h after direct implantation.
In vitro
NSC/MSC co-culture without TNFα stimulation showed a 
statistically signifi cant increase in NFκB activity (P = 0.0004). 
RNA extraction. RNA was isolated from MSCs alone, 
NSCs alone, MSCs grown in co-culture with NSCs and then 
separated, and NSCs grown in co-culture with MSCs and 
then separated using RNA-Bee (Tel-Test, Inc., Friendswood, 
TX) and following the manufacturer’s suggested protocol. 
All cell separations were performed using a BD Infl uxTM 
cell sorter (BD Biosciences, San Jose, CA) utilizing CD29 and 
Stro-1 as MSC identifying markers. After isolation of RNA, 
samples were immediately treated with DNase (to remove 
genomic DNA contamination) and an RNAse inhibitor and 
stored at −80°C until time of use.
Real-time quantitative PCR. Specifi c quantitative assays 
for IL-6 and 36b4 were developed using Beacon Designer, 
AlleleID (Premier Biosoft, Palo Alto, CA), or RealTimeDesign 
(Biosearch Technologies, Novato, CA) based on the NCBI 
refseq sequences. Assay-specifi c information is provided in 
Table 1.
cDNA was synthesized in 10 μL total volume by reverse 
transcription of 1 μL of the RNA stock solution using 300 
nM specifi c reverse primer, 500 μM dNTPs Superscript II 
buffer and Superscript II reverse transcriptase (Invitrogen, 
Carlsbad, CA). Each sample was assayed in triplicate plus 
a control without reverse transcriptase to access for DNA 
contamination. Each plate also contained an assay-specifi c 
sDNA (synthetic amplicon oligo) standard spanning a 5-log 
template concentration range and a no template PCR control. 
Each plate was covered and incubated for 30 min at 50°C fol-
lowed by 75°C for 10 min.
The total volume of reaction (10 μL) was added to 40 μL 
of PCR mix containing 1× PCR buffer, 300 nM forward and 
reverse primers, 3 mM MgCl2, Taq Polymerase, and 100 nM 
fl uorogenic probe. Amplifi cation and quantitation based on 
real-time monitoring of amplifi cation was carried out using 
an ABI Prism 7700 (Applied Biosystems, Foster City, CA) 
using the following cycling conditions: 1 min at 95°C fol-
lowed by 40 cycles of 95°C for 12 s and 60°C for 30 seconds. 
Values of transcripts in unknown samples was obtained by 
interpolating their Ct (PCR cycles to threshold) values on a 
standard curve derived from known amounts of cognate, 
specifi c amplicons. Transcript levels were normalized to the 
level of 36b4 RNA. All determinations were performed in 
triplicate and with a no RT control.
Proliferation assay. The percentage of NSCs actively prolifer-
ating (S phase) when in co-culture with MSCs was calculated 
using Click-iTTM EdU Flow Cytometry Assay Kit (Invitrogen, 
Carlsbad, CA). The manufacturer’s protocol was followed. 
In brief, NSCs were placed in co-culture with MSCs as de-
scribed earlier in this manuscript. One group was stimulated 
Table 1. Quantitative Assays for IL-6 and 36b4 Developed for Quantitative Real-Time 
Polymerase Chain Reaction (qPCR)
Transcript IL-6 36B4
Accn. # NM_012289 NM_022402
Forward primer AGCCAGTTGCCTTCTTGG AGAGGTGCTGGACATCACAG
Reverse primer CCTCTCCGGACTTGTGAAG CATTGCGGACACCCTCTAG
Fluorogenic probe FAM-ACTGATGTTGTTGACAGCCACTGCC-BHQ1 FAM-CAGGCCCTGCACACTCGCTT-BHQ1
Amplicon length 74 62
Lowest limit of detection 200 230
PCR effi ciency ~100% 99%
Sequences of forward primer, reverse primer, and probe.
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Table 2. Cytokine Concentrations (pg/mL) Measured in Brain Tissue 
Supernatant From the Direct Injury and Penumbral Areas
 IL-1α IL-1β IL-6 TNFα
Direct injury area
Sham injury
  5 ± 1*   28 ± 4*   34 ± 3*  25 ± 1*
Direct injury area
CCI + vehicle control
129 ± 32 3,292 ± 720 323 ± 59 77 ± 9
Direct injury area
CCI + MSC implantation
183 ± 28 3,344 ± 517   603 ± 96* 58 ± 8
Penumbral area
Sham injury
  4 ± 0.2   25 ± 2* 29 ± 3   29 ± 2*
Penumbral area
CCI + vehicle control
  37 ± 10 1,004 ± 328 131 ± 17 45 ± 7
Penumbral area
CCI + MSC implantation
 121 ± 19*   2,059 ± 268*   291 ± 45* 52 ± 3
Data analysis shows an increase in interleukin 6 (IL-6) found in the direct injury area 
after mesenchymal stem cell (MSC) implantation as well as an increase in IL-1α, IL-1β, 
and IL-6 found in the penumbral area.
Abbreviation: CCI, controlled cortical impact.
*Indicates signifi cant difference (P < 0.05) in cytokine production when compared to 





FIG. 1. Mesenchymal stromal cells (MSCs) double labeled: 
red with quantum dots, green with green fl uorescent protein. 
Nuclei stained with 4′,6-diamidino-2-phenylindole (DAPI). 
(A) Fifty-eight percent of the MSCs were located in the ven-
tricles. (B) MSCs located around the needle track transvers-































FIG. 2. Nuclear factor kappa B (NFκB) fi refl y luciferase 
activity divided by Renilla luciferase activity measured in 
neuronal stem cell (NSC)/mesenchymal stromal cell (MSC) 
co-cultures. (A) Difference is found between unstimulated 
contact cultures and transwell cultures. (B) Difference is 
found between neuronal stem cells (NSCs) transfected with 
NFκB alone and NSCs transfected with IKKβ.
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In order to evaluate the production of proinfl ammatory 
cytokines in vitro, Bio-Plex cytokine analysis was com-
pleted analyzing culture media from NSC/MSC co-cultures 
that had been stimulated for 6 h with TNFα. A signifi cant 
increase in IL 1-α production is observed with co-culture; 
however, this observation is likely due to an additive effect. 
Additionally, while NSCs and MSCs alone in culture do not 
produce IL-6, an increase in IL-6 production is observed 
with increasing MSC dosage in co-culture (P = 0.002). 
Table 3 shows infl ammatory cytokine production measured 
in NSC/MSC co-cultures.
While the in vitro cytokine data clearly show an increase 
in IL-6, it is not possible to clearly identify NSCs or MSCs as 
the source of production. To evaluate the potential source, 
an IL-6 antibody was incubated in the co-cultures after 
stimulation for 6 h with TNFα. Figure 3 shows IL-6 produc-
tion (represented by FITC green stain) from the NSCs only 
when in direct contact with the underlying MSCs (stained 
red). Therefore, it appears that MSCs are potentially stim-
ulating the NSCs to produce and secrete IL-6 via direct 
contact. In order to quantify the source of IL-6 production, 
NSC/MSC co-cultures were stimulated for 6 h with TNFα 
followed by fl ow cytometric cell sorting based upon MSC 
CD29 and Stro-1 positivity. Next, a real-time quantitative 
PCR was completed to measure the amount of IL-6 produc-
tion from both MSCs and NSCs. Figure 4 shows that MSCs 
and NSCs placed alone in monoculture had minimal IL-6 
production; however, when placed in direct contact cul-
ture, a signifi cant increase in IL-6 production was found 
generated primarily from the MSC population. It is also 
important to note that a signifi cant increase (P = 0.037) in 
NSC IL-6 production was noted when placed in direct con-
tact culture with MSCs.
Figure 5A shows that stimulation of NSCs with TNFα 
caused a trend toward increased proliferation as indicated 
by percentage of cells found in the synthesis (S) phase of the 
cell cycle. The trend reaches signifi cance (P = 0.01) at high 
MSC co-culture concentrations; however, no dose-related 
difference between MSC concentration was found.
NSC/MSC co-cultures stressed with oxygen/glucose 
deprivation for 6 h showed a signifi cant decrease in the frac-
tion of apoptotic NSCs (0.197) when compared to NSC cul-
tured alone (0.382; P = 0.001). Figure 5B–5C shows the fl ow 
cytometry overlays displaying the decreased NSC apoptotic 
fraction.
Additionally, similar co-cultures that were stimulated with 
TNFα showed a potential dose response as NFκB activity 
initially increased (P = 0.005 calculated with 12,500 MSCs 
in co-culture) but returned to control levels with increasing 
amounts of MSCs. Transwell (non-contact) NSC/MSC co-
cultures showed no difference in NFκB activity for any MSC 
concentration. Figure 2A compares NFκB activity between 
direct NSC/MSC co-cultures (stimulated and unstimulated) 
and transwell co-cultures. No difference was found between 
stimulated and unstimulated direct co-cultures at any MSC 
concentration; however, difference between unstimulated 
controls and transwell cultures was noted with increasing 
MSC concentration.
Figure 2B compares NSC/MSC direct contact co-cultures 
after stimulation with TNFα. The NSC populations were 
transfected with dominant vectors for IKKβ, AKT, and a 
PI3 kinase inhibitor (PI3). A difference between NSCs trans-
fected with the dominant negative vector for IKKβ and the 
NFκB vector alone was observed at an MSC concentration 
of 12,500 (P = 0.002). No difference was noted between the 
AKT and NFκB vectors for any MSC concentration.
Table 3. Cytokine Production Measured in Media From Neuronal Stem 
Cell (NSC)/Mesenchymal Stromal Cell (MSC) Co-Cultures Stimulated 
With Tumor Necrosis Factor Alpha (TNFα) for 6 h
 IL-1α IL-1β IL-6
NSCs alone 3.1 ± 0.66 5.9 ± 0.79 0 ± 0
MSCs alone 2.4 ± 0.31 3.1 ± 0.32 0 ± 0
6,250 MSCs  6.5 ± 0.98* 4.3 ± 0.39 2.4 × 104 ± 2.3 × 104
12,500 MSCs   6.4 ± 0.48* 3.7 ± 0.59 1.4 × 1010 ± 1.0 × 1010
25,000 MSCs  5.9 ± 0.54* 4.0 ± 0.42   3.8 × 1018 ± 1.6 × 1018*
An increase in interleukin (IL) 1-α with co-culture that is likely due to an additive 
effect. Signifi cant increase in IL-6 production is observed with increasing MSC dosage.
*Indicates signifi cant difference (P < 0.05) in cytokine production when compared to 
NSC culture alone based upon ANOVA with Tukey Kramer post hoc.
50 μm
FIG. 3. Neuronal stem cells (NSCs) in direct contact culture 
with mesenchymal stromal cells (MSCs; stained red with 
conjugated CD29-PE antibody). Interleukin (IL)-6 secretion 
is localized to the NSC (stained green with IL-6 antibody 
with FITC secondary). Nuclei stained with 4′,6-diamidino-2-
phenylindole (DAPI) blue (40× magnifi cation).
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observed increase in cytokine production could also be due 
to further parenchymal injury secondary to the cellular in-
jection. A third potential explanation could be the activation 
of resident neuronal cells by the implanted MSCs to up-reg-
ulate cytokine production.
In vitro
The observed increase in proinfl ammatory cytokine lev-
els could be produced by resident neuronal cells that come 
into contact with the implanted MSCs. Therefore, to inves-
tigate the possible activation of resident cell niches, NSCs 
(representing neuronal cell lineages) were transfected with 
the aforementioned NFκB vectors. NSC NFκB activity in-
creased with rising MSC concentration in direct co-culture 
regardless of stimulation by TNFα; however, no increase in 
Discussion
In vivo
While initial in vivo research investigating the intrave-
nous infusion of MSCs has shown potential neuroprotection 
via up-regulation of the anti-infl ammatory response [13], 
our data show an increase in the proinfl ammatory cytok-
ines IL-1α, IL-1β, and IL-6 after direct implantation of MSCs 
in a rat TBI model. Immunohistochemistry showed that very 
few (3%–5%) of the implanted MSCs remained within the 
brain with the majority of cells (58%) found in the ventri-
cles (Fig. 1). The small proportion of MSCs that engrafted in 
the parenchymal tissue was located adjacent to the needle 
tracts (Fig. 1). The distribution of cells could indicate that 
only a few engrafted MSCs are capable of secreting signif-
























  Co-Cultured NSCs Co-Cultured MSCs MSCs Alone  
FIG. 4. Real-time quantitative polymer-
ase chain reaction (qPCR) for interleukin 
6 (IL-6) production from mesenchymal 
stromal cell (MSC) and neuronal stem cell 
(NSC) monocultures as well as NSC/MSC 
direct contact co-cultures after fl ow cyto-
metric sorting based upon MSC CD29 and 
Stro-1 positivity. Minimal IL-6 production 
is observed with MSC and NSC monocul-
tures; however, NSC/MSC co-cultures 




























45 FIG. 5. (A) EDU assay shows an increase in 
neuronal stem cell (NSC) proliferation when 
stimulated with tumor necrosis factor alpha 
(TNFα); however, mesenchymal stem cell 
(MSC) co-culture has no effect. (B and C) Flow 
cytometric histogram overlays for NSC cas-
pase 3 expression. Gray area (isotype control). 
Transparent overlay (apoptotic fraction). (B) 
NSCs cultured alone. (C) NSCs/MSC contact 
culture. *P < 0.05.
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Quantitative PCR has shown that the implanted MSCs are 
the primary source of IL-6 production; however, a signifi -
cant increase in NSC IL-6 production when compared to 
monocultures was observed. Immunohistochemistry con-
fi rms NSC activation and IL-6 production (Fig. 3).
To further investigate the potential functional effect of 
NSC NFκB activation, both EdU proliferation assay and 
caspase 3 apoptosis assay were completed. Figure 5A shows 
that co-culture with MSCs does not affect the proliferative 
rate. Conversely, Figure 5C shows a signifi cant decrease in 
the NSC apoptotic rate (P = 0.001) when compared to NSCs 
cultured alone. Therefore, the observed increase in NSC 
NFκB activity appears to stimulate production of the in-
fl ammatory cytokine IL-6 and promote neuroprotection by 
decreasing apoptosis.
Conclusions
Initial in vivo investigation into the direct implantation of 
bone marrow-derived MSCs has shown mixed results [14,23] 
and remains highly controversial. Our data have shown that 
MSCs potentially activate NFκB in resident NSC niches via 
activity was noted when the cells were placed in transwell 
(non-contact) culture (Fig. 2A). Our data show that the pres-
ence of MSCs alone cause NSC NFκB activation and that di-
rect cell-to-cell contact is required for MSC therapy to have 
an effect.
Furthermore, attenuation of NFκB activity was seen with 
the dominant negative IKKβ proving that the observed lumi-
nescence was due to activation of the NFκB fi refl y luciferase. 
No difference was observed between NSCs transfected with 
dominant negative vectors for PI3 kinase and AKT show-
ing that the observed NFκB activation is independent of 
the AKT/PI3 kinase pathway (Fig. 2B). Figure 6 outlines the 
NFκB pathway.
While NSC NFκB activation could lead to increased cyto-
kine production, it is a transcription factor that is common 
to several pathways (cellular proliferation and apoptosis) 
and not specifi c for an infl ammatory response. In order to 
evaluate the functional effect of NFκB activation, a Bio-Plex 
cytokine assay was completed. Supernatant collected from 
NSCs or MSCs alone in culture showed no signifi cant cyto-
kine production; however, NSC/MSC co-cultures showed a 
signifi cant increase in IL-6 production (Table 2; P = 0.002). 
TNF-α 
Dominant Negative P13 Kinase 
Dominant Negative AKT 
X 













– Increased IL-6 Production 
– Decreased Apoptotic Rate 
Toll Like Receptor 
Cellular Membrance 
FIG. 6. Nuclear factor kappa B (NFκB) pathway detailing the point of action for the dominant negatives vectors IKKβ, 
AKT, and the PI3 kinase inhibitor. Activation of the neuronal stem cell (NSC) NFκB pathway leads to increased IL-6 produc-
tion and decreased apoptosis thereby enhancing neuroprotection.
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direct contact. In addition, the in vitro data show that the in-
crease in NFκB activity leads to an increase in NSC-derived 
IL-6 with a concurrent reduction in apoptosis.
Previous research using a cryolesion model has shown 
that IL-6 production has been associated with improved 
wound healing, decreased apoptosis, and a decrease in ox-
idative species for acute neuropathological conditions like 
TBI [24]. Furthermore, similar experiments using an IL-6 
knockout mouse have shown decreased monocyte recruit-
ment and glial cell activation leading to decreased neuronal 
cell survival and wound healing with increased oxidative 
stress [25]. Our results show that the direct implantation of 
MSCs leads to resident neuronal cell activation and IL-6 se-
cretion leading to enhanced neuroprotection.
Optimization of progenitor cell delivery is a fi eld requir-
ing further investigation. Intravenous infusion offers a min-
imally invasive vehicle with the potential of widespread 
distribution [26]; however, a clinically limited number of cells 
reach the arterial system due to a signifi cant fi rst pass pul-
monary effect [27]. Intra-arterial infusion could bypass the 
lungs allowing for more focused delivery and enhanced cel-
lular engraftment [28]; however, high cerebral engraftment 
rates are associated with impedance of cerebral microvas-
cular blood fl ow [29]. Direct intracerebral implantation via 
stereotactic injection would allow for focused delivery with 
the potential for high levels of engraftment.
Due to the observed decrease in apoptosis and neuropro-
tective effects of IL-6 after acute neuropathologic insult, the 
direct implantation of progenitor cells is an attractive vehi-
cle of delivery. Furthermore, the observed effect required 
only limited progenitor cell engraftment. Additional 
research into the implantation of progenitor cell-seeded 
nanofi ber scaffolds could enhance engraftment and poten-
tiate neuroprotection. Overall, direct implantation of bone 
marrow-derived MSCs appears to enhance neuroprotection 
via activation of resident NSC NFκB leading to decreased 
apoptosis and improved cell viability.
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